ERBB2 and gastric cancer: Trastuzumab combined with capecitabine maintenance therapy followed up for more than 16 months.<h4>Conclusion</h4>HAIC plus trastuzumab may be a tolerable treatment option for patients with severe liver metastases from HER2-positive gastric cancer to achieve local control and prolong survival.